TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Surgical skills performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Difficulty concentrating, remembering, or making decisions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Ever repeating a grade level
Endpoint domain: Life impact
Endpoint subdomain: Educational outcomes
Primary endpoint: Hospitalization rates at 180 days
Endpoint domain: Mortality/survival
Primary endpoint: Emergency department (ED) visit rates at 180 days
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative transfused volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Transfusion free status at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peer support satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Detection of new microcracks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average consent rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: QT interval and QTc interval stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in anemia and biochemical markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VSS score of wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic insulin resistance (hepatic-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: efavirenz clearance (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent of participants with mid-interval efavirenz concentrations >1mg/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose received in EXE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant benefit on the uwMRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unfavourable outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of POPF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first peak medial contact force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: second peak medial contact force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in VO2 peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased time trial distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean VIS scores at 72 Hours postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PaO2/FiO2 ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of FT3 FT4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of times of rescue analgesics in the first 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mid-infusion adjustments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum α‐tocopherol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NF‐κB p65 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gastrointestinal disturbances
Endpoint domain: Adverse events/effects
Primary endpoint: Mean 7-month weight change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disability Rating Scale (DRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative incidence of hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction of inflammatory cell infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Intradialytic hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: functional ability and performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting plasma IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postprandial plasma IL-1β
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postprandial plasma IL-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postprandial plasma TNF-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduced risk of receiving appropriate ICD shocks
Endpoint domain: Adverse events/effects
Primary endpoint: health information disclosure intention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: privacy concerns
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time spent on TMT‐A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of words on the verbal fluency task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on MoCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportionality of plasma concentrations for trazodone and gabapentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of pharmacokinetic interaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % Predicted Peak Expiratory Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fish/seafood consumption patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of inflammatory factors (CRP, TNF‐α, IL‐6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Periodontal gingival condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total body lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total body bone mineral content (BMC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: freedom from biochemical recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 28-day seizure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hepatic DNL inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of GIP in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of 3 or more lines in mesopic DCNVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in calibration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of first epidural infusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for additional PCEA bolus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean difference in %BMIp95
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease in BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recovery within 2 weeks after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until return to work within 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent symptoms at 6 months after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: protective behaviors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean increase in 24 hr urine volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects reporting difficulty remembering to drink
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CS-Related Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: albuminuria changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: serum NT-proBNP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nociceptive trigeminal activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of life utility index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: reduction in hot flushes and sweating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Surgical Site Infections (SSIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of developing pancreatic cancer
Endpoint domain: Mortality/survival
Primary endpoint: Molecular Distance to Health scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Food impactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Endoscopic severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: benefit from written naming/spelling therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of iris scan identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of iris scanning operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of iris scan technology
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Camera path length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: differentiation of inflamed and noninflamed joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median core infarct volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median penumbra volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of CURCUGEN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0‐t of CURCUGEN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative bioavailability of CURCUGEN for total THC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycated Hemoglobin A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness and safety of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPTSD disturbances in self-organization symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative self-concept
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: disturbances in relationships
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: high-grade ureteral injury
Endpoint domain: Adverse events/effects
Primary endpoint: ureteral stricture formation
Endpoint domain: Adverse events/effects
Primary endpoint: HIV prevalence among children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events (AEs) occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment non-adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Time in Range (TIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Time < 54 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Labor pain during the active phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of the active phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in intrusive thoughts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proinflammatory gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sustained complete remission (CR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite death or HFH
Endpoint domain: Mortality/survival
Primary endpoint: Residual MR severity at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine sulfate consumption as rescue analgesia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Corneal resistance factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived effectiveness of techniques
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incident urolithiasis events
Endpoint domain: Adverse events/effects
Primary endpoint: Diarrhoea incidence in the last 15 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Volume of vertebroplasties
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Volume of kyphoplasties
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total payment for vertebroplasties
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total payment for kyphoplasties
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of POC VL testing and task-shifting
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in number of clinic visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Encouragement of adherence among clients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PDSS-2 score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional reactions to overdose event
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient comfort during retinal examination
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decreases in glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decreases in insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decreases in HOMA‐IR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Free urine DID
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urgency scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nightly nocturia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful first attempt rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for DLT insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS of DLT delivery and insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fat-free mass (FFM) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self‐report mood measures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of hemidiaphragmatic paralysis postblock
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of bedside pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor block score in upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: strategy success with RA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: need for bail-out RA
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: union rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean time to union
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: pain freedom at 120 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haem-A-QoL Physical Health (PH) score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Grade 3 injection site redness postdose 2
Endpoint domain: Adverse events/effects
Primary endpoint: Moderate to severe headache day frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolapse symptom severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in-hospital case fatality
Endpoint domain: Mortality/survival
Primary endpoint: requirement of mechanical ventilation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Feasibility of classroom-based PA breaks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Acceptability of classroom-based PA breaks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in rates of Levels 1 to 3 hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose nadir improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin peak reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in average IDEA scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to visualize the glottic opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for manoeuvres to facilitate intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incident Atrial Fibrillation (AF) events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Wear time of DSD dressing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient preference for DSD vs comparator
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinically significant electrolyte disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Child-reported pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in tender midfoot and ankle joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oropharyngeal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCA (Minimum Cross-sectional Area)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of glottal injury
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative hoarseness
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of local recurrence at 10 years
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of systemic relapse
Endpoint domain: Mortality/survival
Primary endpoint: Fractional Anisotropy (rFA) in PLIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apnea-Hypopnea Index (AHI) during REM sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean daytime sleep latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vocal cord injuries
Endpoint domain: Adverse events/effects
Primary endpoint: eating behaviors and well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lean mass (LM) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of primary endoscopy for EGC detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discouragement from wanting to eat red meat
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Relative energy intake (EI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection Site Pain (ISP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced test numbers
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in OSAS classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: stress-induced RSFC changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Early time to remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unplanned hospital transfer or death
Endpoint domain: Mortality/survival
Primary endpoint: post-treatment participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Levels of Hct and Hb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: adequate bowel preparation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: bowel cleanliness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: emotional Stroop performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning